Home>Topics>Finance>Food>Food And Drug Administration

Food And Drug Administration

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
  1. Reformulated Diet Pepsi May Be Short-Term Win, but Has Little Long-Run Impact; Stock Fairly Valued

    Commentary

    Fri, 24 Apr 2015

    safety of aspartame--an increasingly common complaint against the sweetener--under current U.S. Food and Drug Administration guidelines, the American Cancer Society estimates that an adult weighing 165 pounds would have to consume

  2. U.S. FDA warns five companies over BMPEA stimulant in supplements

    Headlines

    Thu, 23 Apr 2015

    WASHINGTON, April 23 (Reuters) - The U.S. Food and Drug Administration warned five companies on Thursday to stop selling dietary supplements containing an unapproved stimulant known as beta-methylphenylethylamine, or BMPEA.

  3. CORRECTED- FDA grants priority review to Boehringer's drug to reverse blood thinning

    Headlines

    Thu, 23 Apr 2015

    April 23 (Reuters) - Boehringer Ingelheim Pharmaceuticals Inc said its drug to reverse blood thinning was granted a priority review status by the U.S. Food and Drug Administration , accelerating the regulatory process by four months.

  4. Novartis Posts Solid 1Q as the Divestiture of Lower-Margin Businesses Expands Margins

    Commentary

    Thu, 23 Apr 2015

    LCZ696 holds the potential for annual sales over $5 billion. The accelerated reviews by the regulatory agencies and no expected FDA review panel increases our conviction that the medical community will embrace the drug. Additionally, immunology drug Cosentyx

  5. BRIEF-Eckert & Ziegler's SagiNova afterloader receives FDA market clearance

    Headlines

    Thu, 23 Apr 2015

    April 23 (Reuters) - Eckert & Ziegler Strahlen und Medizintechnik AG :

  6. Amgen Shares Still Look Undervalued

    Headlines

    Wed, 22 Apr 2015

    progress. The biggest launch of the year is likely to be PCSK9 antibody Repatha, which could receive Food and Drug Administration approval in August. While Sanofi and Regeneron are poised to launch a similar product in July, we think

  7. Amgen Outperforms in 1Q, Raises Guidance; Maintaining Our Fair Value Estimate

    Commentary

    Wed, 22 Apr 2015

    progress. The biggest launch of the year is likely to be PCSK9 antibody Repatha, which could receive Food and Drug Administration approval in August. While Sanofi and Regeneron are poised to launch a similar product in July, we think

  8. Teva Pursues Mylan as Generic Copaxone Competition Nears

    Commentary

    Tue, 21 Apr 2015

    Teva’s $82 per share takeover bid (50% cash and 50% stock) for Mylan just days after the U.S. Food and Drug Administration approved a generic version of Teva’s Copaxone suggests that management wants to assure investors it has a

  9. An Observation

    Commentary

    Mon, 20 Apr 2015

    Breakthroughs ETF. The ALPS Medical Breakthroughs ETF (SBIO) targets biotech companies with drugs in Phase II and Phase III of FDA clinical trials. The fund limits itself to US-listed companies with market caps between $200M and $5B. SBIO also has screens

  10. BRIEF-Biofrontera establishes subsidiary in the U.S.

    Headlines

    Mon, 20 Apr 2015

    * Biofrontera Inc., registered in Wilmington, Delaware is intended to lay ground for marketing and sales activities upon expected FDA approval for products Ameluz and BF-Rhodoled in 2016 Source text...

« Prev12345Next »
Content Partners